-
2
-
-
1542400364
-
Pimecrolimus for the treatment of inflammatory skin disease
-
WOLFF K, STUETZ A: Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin. Pharmacother. (2004) 5(3):643-655.
-
(2004)
Expert Opin. Pharmacother
, vol.5
, Issue.3
, pp. 643-655
-
-
WOLFF, K.1
STUETZ, A.2
-
3
-
-
14844315610
-
Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: Meta-analysis of randomised controlled trials
-
ASHCROFT DM, DIMMOCK P, GARSIDE R, STEIN K, WILLIAMS HC: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. (2005) 330:516.
-
(2005)
BMJ
, vol.330
, pp. 516
-
-
ASHCROFT, D.M.1
DIMMOCK, P.2
GARSIDE, R.3
STEIN, K.4
WILLIAMS, H.C.5
-
4
-
-
33749361700
-
Topical pimecrolimus for skin disease other than atopic dermatitis
-
WOLLINA U, HANSEL G, KOCH A, ABDEL-NASER MB: Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin. Pharmacother. (2006) 7(14):1967-1975.
-
(2006)
Expert Opin. Pharmacother
, vol.7
, Issue.14
, pp. 1967-1975
-
-
WOLLINA, U.1
HANSEL, G.2
KOCH, A.3
ABDEL-NASER, M.B.4
-
5
-
-
0000581086
-
The effect of topically applied compound F in selected dermatoses
-
SULZBERGER MB, WITTEN VH: The effect of topically applied compound F in selected dermatoses. J. Invest. Dermatol. (1952) 19(2):101-102.
-
(1952)
J. Invest. Dermatol
, vol.19
, Issue.2
, pp. 101-102
-
-
SULZBERGER, M.B.1
WITTEN, V.H.2
-
6
-
-
0032406844
-
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
-
MROWIETZ U, GRAEBER M, BRAUTIGAM M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol. (1998) 139:992-996.
-
(1998)
Br. J. Dermatol
, vol.139
, pp. 992-996
-
-
MROWIETZ, U.1
GRAEBER, M.2
BRAUTIGAM, M.3
-
7
-
-
17744379151
-
SDZ ASM 981: An emerging safe and effective treatment for aropic dermatitis
-
LUGER T, VAN LEENT EJM, GRAEBER M et al.: SDZ ASM 981: an emerging safe and effective treatment for aropic dermatitis. Br. J. Dermatol. (2001) 144:788-794.
-
(2001)
Br. J. Dermatol
, vol.144
, pp. 788-794
-
-
LUGER, T.1
VAN LEENT, E.J.M.2
GRAEBER, M.3
-
8
-
-
0142025275
-
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion
-
MROWIETZ U, WUSTLICH S, HOEXTER G, GRAEBER M, BRAUTIGAM M, LUGER T: An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta. Derm. Venereol. (2003) 83(5):351-353.
-
(2003)
Acta. Derm. Venereol
, vol.83
, Issue.5
, pp. 351-353
-
-
MROWIETZ, U.1
WUSTLICH, S.2
HOEXTER, G.3
GRAEBER, M.4
BRAUTIGAM, M.5
LUGER, T.6
-
9
-
-
9644257237
-
Pimecrolimus cream 1% versus betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial
-
RIGOPOULOS D, IOANNIDES D, KALOGEROMITROS D, GREGORIOU S, KATSAMBAS A. Pimecrolimus cream 1% versus betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br. J. Dermatol. (2004) 151:1071-1075.
-
(2004)
Br. J. Dermatol
, vol.151
, pp. 1071-1075
-
-
RIGOPOULOS, D.1
IOANNIDES, D.2
KALOGEROMITROS, D.3
GREGORIOU, S.4
KATSAMBAS, A.5
-
10
-
-
3343004623
-
Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis
-
LUGER TA, LAHFA M, FOLSTER-HOLST R et al.: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Dermatolog. Treat. (2004) 15:169-178.
-
(2004)
J. Dermatolog. Treat
, vol.15
, pp. 169-178
-
-
LUGER, T.A.1
LAHFA, M.2
FOLSTER-HOLST, R.3
-
11
-
-
15944426416
-
Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo
-
COSKUN B, SARAL Y, TURGUT D: Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur. J. Dermatol. (2005) 15(2):88-91.
-
(2005)
Eur. J. Dermatol
, vol.15
, Issue.2
, pp. 88-91
-
-
COSKUN, B.1
SARAL, Y.2
TURGUT, D.3
-
12
-
-
33747605048
-
Pimecrolimus cream, 1%, versus hydrocortisone acetate cream, 1%, in the treatment official seborrheic dermatitis: A randomized, investigator-blind, clinical trial
-
FIROOZ A, SOLHPOUR A, GOROUHI F et al.: Pimecrolimus cream, 1%, versus hydrocortisone acetate cream, 1%, in the treatment official seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch. Dermatol. (2006) 142(8):1066-1067.
-
(2006)
Arch. Dermatol
, vol.142
, Issue.8
, pp. 1066-1067
-
-
FIROOZ, A.1
SOLHPOUR, A.2
GOROUHI, F.3
-
13
-
-
33748785967
-
1% Pimecrolimus, 0.005% calcipotriol and 0.1% betamethasone in the treatment of intertriginous psoriasis: A double-blind, randomized controlled study
-
KREUTER A, SOMMER A, HYUN J et al.: 1% Pimecrolimus, 0.005% calcipotriol and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch. Dermatol. (2006) 142(9):1138-1143.
-
(2006)
Arch. Dermatol
, vol.142
, Issue.9
, pp. 1138-1143
-
-
KREUTER, A.1
SOMMER, A.2
HYUN, J.3
-
14
-
-
0242550810
-
Pimecrolimus does not affect Langerhans cells in murine epidermis
-
MEINGASSNER JD, KOWALSKY E, SCHWENDINGER H, ELBE-BURGER A, STUTZ A: Pimecrolimus does not affect Langerhans cells in murine epidermis. Br. J. Dermatol. (2003) 149:853-857.
-
(2003)
Br. J. Dermatol
, vol.149
, pp. 853-857
-
-
MEINGASSNER, J.D.1
KOWALSKY, E.2
SCHWENDINGER, H.3
ELBE-BURGER, A.4
STUTZ, A.5
-
15
-
-
0041825562
-
Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corricosteroids
-
KALTHOFF ES, CHUNG J, MUSSER P, STUETZ A: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corricosteroids. Clin. Exp. Immunol. (2003) 133:350-359.
-
(2003)
Clin. Exp. Immunol
, vol.133
, pp. 350-359
-
-
KALTHOFF, E.S.1
CHUNG, J.2
MUSSER, P.3
STUETZ, A.4
-
16
-
-
1842639441
-
Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells
-
HOETZENECKER W, MEINGASSNER JG, ECKER R, STINGL G, STUETZ A, ELBE-BÜRGER A: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J. Invest. Dermatol. (2004) 122:673-684.
-
(2004)
J. Invest. Dermatol
, vol.122
, pp. 673-684
-
-
HOETZENECKER, W.1
MEINGASSNER, J.G.2
ECKER, R.3
STINGL, G.4
STUETZ, A.5
ELBE-BÜRGER, A.6
-
17
-
-
20444457467
-
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis
-
HOETZENECKER W, ECKER R, STUETZ A, STINGL G, ELBE-BÜRGER A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. (2005) 115:1276-1283.
-
(2005)
J. Allergy Clin. Immunol
, vol.115
, pp. 1276-1283
-
-
HOETZENECKER, W.1
ECKER, R.2
STUETZ, A.3
STINGL, G.4
ELBE-BÜRGER, A.5
-
18
-
-
33644878417
-
Effect of pimecrolimus versus corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function
-
KRUMMEN MBW, VARGA G, STEINERT M, STUETZ A, LUGER TA, GRABBE S: Effect of pimecrolimus versus corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function. Exp. Dermatol. (2006) 15(1):43-50.
-
(2006)
Exp. Dermatol
, vol.15
, Issue.1
, pp. 43-50
-
-
KRUMMEN, M.B.W.1
VARGA, G.2
STEINERT, M.3
STUETZ, A.4
LUGER, T.A.5
GRABBE, S.6
-
19
-
-
33747378525
-
Both pimecrolimus and corticosteroids deplete plasmatocytoid dendritic cells in patients with atopic dermatitis
-
HOETZENECKER W, MEINDL S, STUETZ A, STINGL G, ELBE-BORGERA. Both pimecrolimus and corticosteroids deplete plasmatocytoid dendritic cells in patients with atopic dermatitis. J. Invest. Dermatol. (2006) 126:2141-2144.
-
(2006)
J. Invest. Dermatol
, vol.126
, pp. 2141-2144
-
-
HOETZENECKER, W.1
MEINDL, S.2
STUETZ, A.3
STINGL, G.4
ELBE-BORGERA5
-
21
-
-
32844468634
-
Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation
-
YAROSH D, PENA AV, NAY SL, CANNING MT, BROWN DA: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol. (2005) 125:1020-1025.
-
(2005)
J. Invest. Dermatol
, vol.125
, pp. 1020-1025
-
-
YAROSH, D.1
PENA, A.V.2
NAY, S.L.3
CANNING, M.T.4
BROWN, D.A.5
-
22
-
-
33751303107
-
Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair
-
CANNING MT, NAY SL, PENA AV, YAROSH DB: Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J. Mol. Hist. (2006) 37:285-291.
-
(2006)
J. Mol. Hist
, vol.37
, pp. 285-291
-
-
CANNING, M.T.1
NAY, S.L.2
PENA, A.V.3
YAROSH, D.B.4
-
23
-
-
33745245725
-
Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients
-
DOELKER L, TRAN C, GKOMOUZAS A et al.: Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp. Dermatol. (2006) 15(5):342-346.
-
(2006)
Exp. Dermatol
, vol.15
, Issue.5
, pp. 342-346
-
-
DOELKER, L.1
TRAN, C.2
GKOMOUZAS, A.3
-
24
-
-
33646557042
-
A cost-utility analysis of pimecrolimus versus topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema
-
PITT M, GARSIDE R, STEIN K: A cost-utility analysis of pimecrolimus versus topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br. J. Dermatol. (2006) 154:1137-1146.
-
(2006)
Br. J. Dermatol
, vol.154
, pp. 1137-1146
-
-
PITT, M.1
GARSIDE, R.2
STEIN, K.3
-
25
-
-
33744727361
-
Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids
-
CUNHA PR: Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta. Derm. Venereol. (2006) 86(1):69-70.
-
(2006)
Acta. Derm. Venereol
, vol.86
, Issue.1
, pp. 69-70
-
-
CUNHA, P.R.1
-
26
-
-
0142258867
-
Repigmentation of vitiligo with pimecrolimus cream: A case report
-
MAYORAL FA, GONZALEZ C, SHAH NS, ARCINIEGAS C: Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology (2003) 207(3):322-323.
-
(2003)
Dermatology
, vol.207
, Issue.3
, pp. 322-323
-
-
MAYORAL, F.A.1
GONZALEZ, C.2
SHAH, N.S.3
ARCINIEGAS, C.4
-
27
-
-
8744304117
-
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study
-
GRIBETZ C, LING M, LEBWOHL M et al.: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol. (2004) 51(5):731-738.
-
(2004)
J. Am. Acad. Dermatol
, vol.51
, Issue.5
, pp. 731-738
-
-
GRIBETZ, C.1
LING, M.2
LEBWOHL, M.3
-
28
-
-
0035081866
-
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
-
QUEILLE-ROUSSEL C, PAUL C, DUTEIL L et al.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J Dermatol. (2001) 144:507-513.
-
(2001)
Br. J Dermatol
, vol.144
, pp. 507-513
-
-
QUEILLE-ROUSSEL, C.1
PAUL, C.2
DUTEIL, L.3
-
29
-
-
0036677154
-
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug
-
KAPP A, PAPP K, BINGHAM A et al.: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J. Allergy Clin. Immunol. (2002) 110:277-284.
-
(2002)
J. Allergy Clin. Immunol
, vol.110
, pp. 277-284
-
-
KAPP, A.1
PAPP, K.2
BINGHAM, A.3
-
30
-
-
0036634394
-
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children
-
VAHN U, BOS JD, GOODFIELD M et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 110:e2.
-
(2002)
Pediatrics
, vol.110
-
-
VAHN, U.1
BOS, J.D.2
GOODFIELD, M.3
-
31
-
-
10744225363
-
Pimecrolimus cream 1%: A potential new treatment for chronic hand dermatitis
-
BELSITO DV, FOWLER JF Jr, MARKS JG Jr et al.: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis (2004) 73:31-38.
-
(2004)
Cutis
, vol.73
, pp. 31-38
-
-
BELSITO, D.V.1
FOWLER Jr, J.F.2
MARKS Jr, J.G.3
-
32
-
-
17844383944
-
Randomized controlled trial of pimecrolimus 1% cream for treatment facial acne vulgaris
-
TAN JKL, MORNEAU K, FUNG K: Randomized controlled trial of pimecrolimus 1% cream for treatment facial acne vulgaris. J. Am. Acad. Dermatol. (2005) 52:738-739.
-
(2005)
J. Am. Acad. Dermatol
, vol.52
, pp. 738-739
-
-
TAN, J.K.L.1
MORNEAU, K.2
FUNG, K.3
-
33
-
-
24144433476
-
Topical pimecrolimus in the treatment of genital lichen planus: A prospective case series
-
LONSDALE-ECCLES AA, VELANGI S: Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br. J. Dermatol. (2005) 153:390-394.
-
(2005)
Br. J. Dermatol
, vol.153
, pp. 390-394
-
-
LONSDALE-ECCLES, A.A.1
VELANGI, S.2
|